Patients received two of six treatments in sequence ( 12 weeks each ) : placebo , umeclidinium ( UMEC ) / vilanterol ( VI ) ( 125/25 mcg or 62.5 / 25 mcg ) , VI ( 25 mcg ) or UMEC ( 62.5 mcg or 125 mcg ) .